SyntheX

SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection...

Oncology,synthetic lethality,biotechnology,synthetic biology,cancer genetics,therapeutics,genetic engineering,targeted protein degradation,ras,functional selection,drug discovery,biologics,peptides,molecular glues,and raf

Synthex operates in the Biotechnology research industry.

Synthex's revenue is 11m - 100m

Synthex has 11 - 50 employees.